PMH/502 Week 1: Neurotransmitter Systems and Receptor Pharmacology, sample paper

Why Fifteen Milligrams Sedates More Than Forty-Five: Reading Mirtazapine's Receptor Profile to Explain Its Effects in a 72-Year-Old With Depression, Poor Sleep and Weight Loss

[Student Name]

University of Phoenix

PMH/502: Neuropsychiatric Pharmacology

Week 1 Assignment

[Instructor Name]

[Date]

The patient is a composite written for a model paper.

Mrs. A., a 72-year-old widow, has major depression with early-morning awakening, poor appetite and a 5 kg weight loss over three months. Her primary care clinician started sertraline, which caused nausea and made her appetite worse. As a psychiatric nurse practitioner student, I consider mirtazapine, and this paper explains the receptor pharmacology that makes it a logical choice and the effects to expect.

Neurotransmitter Systems in Depression

Depression involves dysregulation across monoamine systems, serotonin, norepinephrine and dopamine, along with downstream changes in neural plasticity. Most antidepressants act by increasing monoamine signaling, either by blocking reuptake, as selective serotonin reuptake inhibitors do, or by other mechanisms. Mirtazapine takes a different route, and its receptor profile explains both its benefits and its side effects.

Alpha-2 Blockade: The Antidepressant Engine

Presynaptic alpha-2 adrenergic receptors act as brakes on norepinephrine release, and alpha-2 heteroreceptors on serotonin neurons brake serotonin release. Anttila and Leinonen (2001) describe mirtazapine as an antagonist of central presynaptic alpha-2 receptors, which releases these brakes and increases both noradrenergic and serotonergic transmission. This is the proposed basis of its antidepressant effect.

Serotonin Receptor Blockade: Fewer SSRI Side Effects

Mirtazapine also blocks 5-HT2 and 5-HT3 receptors (Anttila & Leinonen, 2001). Stimulation of 5-HT2 receptors contributes to agitation, insomnia and sexual dysfunction, and stimulation of 5-HT3 receptors in the gut and brainstem causes nausea. By blocking these receptors while increasing serotonin release, mirtazapine directs serotonin toward 5-HT1A receptors, associated with antidepressant and anti-anxiety effects, and avoids the nausea and sexual side effects common with SSRIs. For Mrs. A., whose sertraline caused nausea, this matters.

The same drug that lifts serotonin and norepinephrine also blocks the receptors that would have made her sick to her stomach.

Histamine Blockade: Sleep and Appetite

Mirtazapine is a potent antagonist of histamine H1 receptors. H1 blockade causes sedation and increased appetite with weight gain (Anttila & Leinonen, 2001). In a younger patient worried about weight, these are drawbacks; in Mrs. A., with insomnia and weight loss, they are useful effects.

Why Lower Doses Can Be More Sedating

Mirtazapine's affinity for H1 receptors is very high, so H1 blockade is nearly complete at low doses such as 7.5 to 15 mg. As the dose increases, noradrenergic effects from alpha-2 blockade grow and may partly counteract sedation. Clinically, many patients report more sedation at 15 mg than at 30 or 45 mg, although this varies. Knowing this prevents an error: reducing the dose to lessen daytime drowsiness may not help, while increasing it for efficacy may not worsen sedation.

What the Evidence Shows About Efficacy

Watanabe et al. (2011) conducted a Cochrane review comparing mirtazapine with other antidepressants and found that mirtazapine was likely to have a faster onset of action than SSRIs during the early weeks of treatment, with similar overall efficacy, and was associated with more weight gain and sleepiness and less nausea and sexual dysfunction. These findings match what the receptor profile predicts. In a network meta-analysis comparing 21 antidepressants head to head, mirtazapine was among the drugs with somewhat greater efficacy, although differences between agents were modest (Cipriani et al., 2018).

Comparing Receptor Profiles

Contrasting mirtazapine with other antidepressants clarifies how receptor profiles predict effects. Sertraline blocks serotonin reuptake, stimulating all serotonin receptor subtypes, including those causing nausea and sexual effects. Trazodone blocks 5-HT2A and H1 receptors and alpha-1 receptors, causing sedation and orthostatic hypotension, which is why it is used at low doses for sleep. Bupropion acts on norepinephrine and dopamine and lacks antihistamine effects, so it is activating rather than sedating. Mirtazapine's combination of alpha-2, 5-HT2, 5-HT3 and H1 blockade is unusual, which is why its side effect profile differs so much from SSRIs.

Receptor Occupancy and Dose

The relationship between dose and effect depends on how tightly a drug binds each receptor. A receptor bound at very low concentrations will be almost fully occupied at the starting dose, while a receptor with lower affinity will be occupied only as the dose rises. This principle explains mirtazapine's dose-dependent sedation and applies to many psychotropic drugs, including quetiapine, whose sedation at low doses reflects antihistamine binding while antipsychotic effects require higher doses.

Onset of Action

All antidepressants act on receptors within hours, yet mood improvement takes weeks, because the lasting benefit depends on slower adaptations in receptors, signaling and brain plasticity. The Cochrane finding of faster early response with mirtazapine may reflect its effects on sleep and appetite, which improve quickly and contribute to early symptom scores (Watanabe et al., 2011).

Teaching Mrs. A.

I explain that the new medicine may help her sleep and eat within days, that mood improvement usually takes several weeks and that she should get up slowly at night to avoid falls. Her daughter will help watch for excessive drowsiness during the day.

Anticholinergic Burden

Unlike tricyclic antidepressants, mirtazapine has little anticholinergic activity, an advantage in older adults at risk of confusion, constipation and urinary retention.

Interactions

Because several enzymes clear mirtazapine, single-enzyme inhibitors have limited effect on its levels, but combining it with other sedatives, alcohol or opioids adds to sedation and fall risk. I review her medications and find a nightly antihistamine sleep aid, which she stops.

If Mirtazapine Is Not Tolerated

If daytime sedation persists or weight gain becomes excessive, alternatives such as bupropion or a different SSRI at a low dose with an antiemetic strategy could be considered.

Documentation

The note records the reason for the switch, the starting dose and the effects to monitor.

Pharmacokinetics in an Older Adult

Mirtazapine is metabolized by several cytochrome P450 enzymes and cleared by the liver and kidneys. Clearance is reduced in older adults and in kidney or liver impairment, so starting at 7.5 mg in Mrs. A. is reasonable, taken at bedtime.

Risks to Watch

Sedation increases fall risk in older adults, especially at night. Weight gain, desirable now, should be monitored so that it does not become excessive. Mirtazapine can rarely cause low white blood cell counts; fever or sore throat should prompt a blood count. Like other antidepressants, it can cause hyponatremia, and it should not be combined with MAO inhibitors.

The Prescribing Decision

I recommend stopping sertraline and starting mirtazapine 7.5 mg at bedtime, increasing to 15 mg after one week if tolerated, with follow-up in two weeks to assess sleep, appetite, mood and daytime drowsiness and to check for falls.

Conclusion

Mirtazapine's blockade of alpha-2 receptors increases norepinephrine and serotonin release, its blockade of 5-HT2 and 5-HT3 receptors avoids nausea and sexual side effects and its strong histamine H1 blockade causes sedation and appetite gain, strongest at low doses. For Mrs. A., with depression, insomnia, weight loss and SSRI-induced nausea, the receptor profile points to a drug whose side effects are useful effects, supported by review evidence of similar efficacy and faster onset.

References

Anttila, S. A. K., & Leinonen, E. V. J. (2001). A review of the pharmacological and clinical profile of mirtazapine. CNS Drug Reviews, 7(3), 249-264. https://doi.org/10.1111/j.1527-3458.2001.tb00198.x

Cipriani, A., Furukawa, T. A., Salanti, G., Chaimani, A., Atkinson, L. Z., Ogawa, Y., Leucht, S., Ruhe, H. G., Turner, E. H., Higgins, J. P. T., Egger, M., Takeshima, N., Hayasaka, Y., Imai, H., Shinohara, K., Tajika, A., Ioannidis, J. P. A., & Geddes, J. R. (2018). Comparative efficacy and acceptability of 21 antidepressant drugs for the acute treatment of adults with major depressive disorder: A systematic review and network meta-analysis. The Lancet, 391(10128), 1357-1366. https://doi.org/10.1016/S0140-6736(17)32802-7

Watanabe, N., Omori, I. M., Nakagawa, A., Cipriani, A., Barbui, C., Churchill, R., & Furukawa, T. A. (2011). Mirtazapine versus other antidepressive agents for depression. Cochrane Database of Systematic Reviews, 2011(12), Article CD006528. https://doi.org/10.1002/14651858.CD006528.pub2